Pharmaceutical Quality Control Release Testing Service Market Report 2026

The pharmaceutical quality control release testing service market size has grown strongly in recent years. It will grow from $7.55 billion in 2025 to $8.13 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to stricter gmp regulations, rise in global drug production, growth in contract testing labs, increase in biologics testing needs, expansion of generic drug manufacturing.

The pharmaceutical quality control release testing service market size is expected to see strong growth in the next few years. It will grow to $11.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growth in complex biologic pipelines, rising regulatory audit frequency, expansion of outsourced qc models, demand for faster batch release cycles, increased multi region drug approvals. Major trends in the forecast period include automated batch release testing, digital laboratory quality systems, AI assisted analytical validation, connected stability testing labs, smart quality data platforms.

The expansion of cell and gene therapy pipelines is anticipated to drive the growth of the pharmaceutical quality control release testing service market in the coming years. Cell and gene therapy pipelines refer to the cellular and genetic therapeutic products under development and regulatory review for commercialization. The expansion is primarily driven by increasing investment in biotechnology research and development, as pharmaceutical companies and biotech firms allocate substantial resources toward innovative cellular and genetic therapies for previously untreatable conditions. The growing cell and gene therapy pipeline directly increases demand for specialized quality control release testing services to ensure these complex biological products meet stringent safety and efficacy standards before commercialization. For example, in January 2025, according to the American Society of Gene and Cell Therapy, a US-based scientific association, the global gene therapy pipeline reached 2,117 programs in the fourth quarter of 2024, up from 2,041 programs in the third quarter of 2024. Therefore, the expansion of cell and gene therapy pipelines is driving the growth of the pharmaceutical quality control release testing service market.

Companies operating in the pharmaceutical quality control release testing services market are focusing on developing advanced solutions, such as microbiological-based quality control testing, to ensure product sterility, regulatory compliance, and timely batch release. Microbiological-based quality control testing uses microbiological techniques to monitor and measure microbial presence in pharmaceutical products and production settings, which helps confirm sterility, maintain product safety, and meet regulatory requirements before batch release. For example, in March 2025, Nelson Laboratories, a US-based microbiological testing company, introduced Rapid Sterility Testing, a microbiology-based quality control testing offering to modernize sterility assurance processes. It is designed to support faster batch release of sterile pharmaceutical products. The solution shortens traditional fourteen-day incubation timelines to approximately six days and incorporates automated, quantitative data analytics to enhance result precision, reduce manual intervention, and improve overall testing reliability.

In January 2025, Cormica, a UK-based medical device and pharmaceutical testing services company, acquired Focus Laboratories for an undisclosed amount. Through this acquisition, Cormica seeks to expand its pharmaceutical microbiological testing capabilities, strengthen quality control and batch release services, and broaden its presence in the U.S. laboratory testing market by integrating Focus Laboratories’ expertise in rapid microbiology and regulatory consulting. Focus Laboratories is a US-based microbiological testing company providing microbiological testing services and rapid detection solutions for the pharmaceutical and biotechnology sectors.

Major companies operating in the pharmaceutical quality control release testing service market are Labcorp Holdings Inc., SGS S.A., Eurofins Scientific SE, Selvita S.A., WuXi AppTec Co. Ltd., Intertek Group plc, Charles River Laboratories International Inc., Piramal Pharma Limited, Siegfried Holding AG, Almac Group Limited, NSF International, ClinChoice Inc., BioAgilytix Inc., Microbac Laboratories Inc., ARL Bio Pharma Inc., Quality Chemical Laboratories LLC, Neopharm Labs Inc., Butterworth Laboratories Limited, Cambridge Polymer Group Inc., Honeyman Group Limited, and Element Materials Technology Group Limited.

Tariffs on laboratory instruments, chromatography systems, and testing reagents are increasing operational costs in pharmaceutical quality control release testing services. Advanced analytical and stability testing segments are most affected due to reliance on imported equipment. Regions dependent on imported lab technologies face higher setup and service pricing. This can slow capacity expansion for independent testing providers. At the same time, tariffs are encouraging local sourcing of lab supplies and regional testing infrastructure growth.

The pharmaceutical quality control release testing service market research report is one of a series of new reports that provides pharmaceutical quality control release testing service market statistics, including pharmaceutical quality control release testing service industry global market size, regional shares, competitors with a pharmaceutical quality control release testing service market share, detailed pharmaceutical quality control release testing service market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical quality control release testing service industry. This pharmaceutical quality control release testing service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical quality control release testing service is a specialized offering that verifies that pharmaceutical products comply with predefined quality, safety, and regulatory standards prior to commercial release. It involves systematic testing and analysis of raw materials, in-process samples, and finished drugs to confirm identity, strength, purity, potency, and regulatory adherence. These services support manufacturers in maintaining product quality, safeguarding patient safety, and meeting global regulatory requirements in complex production environments.

The primary product types of pharmaceutical quality control release testing services include dissolution testing, anti-corrosion testing, ICH stability storage and testing, and other product types. Dissolution testing refers to analytical procedures that measure the rate at which active pharmaceutical ingredients (APIs) are released from dosage forms to confirm efficacy and safety. These services are provided under service categories including analytical testing services, microbiological testing services, stability testing services, and sterility testing services. They employ technologies such as gas chromatography (GC), mass spectrometry (MS), and multiple spectroscopy techniques, and are utilized by end users including pharmaceutical manufacturers, biotechnology companies, contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and research and academic institutions.

The pharmaceutical quality control release testing service market includes revenues earned by entities by providing services, such as analytical testing, stability testing, microbiological testing, method development and validation, impurity profiling, formulation testing, batch release testing, regulatory compliance support, stability storage services, and pharmacopeial testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.